Ross Wilson is an Assistant Adjunct Professor of Molecular and Cell Biology at the University of California, Berkeley, and Director of Therapeutic Delivery at the IGI. He is working to enable widespread clinical use of genome editing, which is currently limited by the difficulty in delivering therapeutic enzymes to the cells in need of correction. To address this need, the Wilson lab is engineering CRISPR enzymes to create effective methods of administration that will facilitate targeted delivery to specific cells, tissues, or organs.
Ross obtained his B.S. in Biochemistry and his Ph.D. in Biochemistry at The Ohio State University. He then studied the roles of protein components in the biogenesis of microRNAs, small molecules that carry out genetic regulation as a postdoctoral scholar in Jennifer Doudna’s lab.
At the IGI, Ross leads the development of new technologies for tissue-specific delivery of genome-editing enzymes such as Cas9. The Wilson lab’s goals also include liver-targeted delivery, delivery targeted to immune cells, and improving access to genetic therapies.